Plasma TNF-α, Adiponectin Levels Influence Risk for Psoriatic Arthritis, Psoriasis
The investigators sought to determine whether TNF-α and adiponectin levels might play a role in differentiating psoriatic arthritis from psoriasis.
Systemic Diseases
SYSTEMIC DISEASES
FEATURE ARTICLE
LATEST NEWS
B-Cell Depletion Therapy With Rituximab Effective for Cutaneous Lupus Erythematosus
Although patients with CCLE responded well, the numbers were small and additional research with respect to this finding is warranted.
Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
Assessment of Pediatric Cutaneous Lupus With CLASI Easier, More Reliable Than PGA
A majority of the physician participants reported that CLASI was an easier tool to use compared with PGA.
Depression Risk High in Cutaneous, Systemic Lupus Erythematosus
The risk for depression was increased significantly in patients with systemic lupus erythematosus and cutaneous lupus erythematosus.
Prevalence of Psoriatic Arthritis Quantified in Patients With Psoriasis
Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.
Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA
The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.
Baseline Characteristics Associated With Response to Biologic Therapy in PsA
Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.
CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis
The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.
Belimumab Aids Anti-dsDNA-Positive Hypocomplementemic Lupus
Weekly belimumab is associated with greater benefit than placebo for patients with hypocomplementemic/anti-double stranded (ds)DNA-positive systemic lupus erythematosus.
Want to read more?
Please login or register first to view this content.
Next post in Systemic Diseases
